Logotype for Swedish Orphan Biovitrum

SOBI (SOBI) Q4 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Swedish Orphan Biovitrum

Q4 2024 earnings summary

30 Jun, 2026

Executive summary

  • Achieved full-year 2024 revenue growth of 19% to SEK 26,027M, with Q4 revenue up 8% year-over-year at constant exchange rates.

  • Adjusted EBITDA/EBITA margin was 36% for the year and 34% in Q4, reflecting strong portfolio performance and ongoing investments.

  • Strategic growth portfolio expanded rapidly, now representing up to 55% of Q4 revenues, driven by launches and new indications.

  • Significant pipeline progress with multiple regulatory filings and launches, including Altuvoct, Aspaveli, and Gamifant.

  • Board proposes no dividend for 2024; David Meek elected as new Chair.

Financial highlights

  • Q4 revenues reached SEK 7,436M, surpassing SEK 7 billion in a single quarter for the first time.

  • Profit for the period was SEK 3,879M for FY 2024, up 36% year-over-year; Q4 profit SEK 1,391M, up 36%.

  • Adjusted EPS before dilution for FY 2024 was SEK 11.83, up 26%; Q4 adjusted EPS SEK 4.03, up 26%.

  • Operating cash flow for FY 2024 was SEK 7,388M, up 67% year-over-year.

  • Net debt reduced to SEK 15,194M from SEK 19,265M at the end of 2023; net debt/EBITDA at 1.6x.

Outlook and guidance

  • 2025 revenue expected to grow at a high single-digit percentage at constant exchange rates.

  • Adjusted EBITDA/EBITA margin for 2025 guided to mid-30s, reflecting continued investment in launches and R&D.

  • Margin expansion anticipated beyond 2025 as scale increases and launch-related expenses moderate.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more